You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu

News

Positive data for AnaMar’s fibrosis therapy

AnaMar has announced positive results from its phase 1 research relating to the use of its peripheral 5-HT2B receptor antagonist, AM1476, as a treatment for systemic sclerosis (SSc) characterised by lung and skin fibrosis.